Suppr
超能文献

Adjuvant Immunotherapy for Kidney Cancer - A New Strategy with New Challenges.

作者信息

Voss Martin H, Motzer Robert J

机构信息

From Memorial Sloan Kettering Cancer Center, New York.

出版信息

N Engl J Med. 2024 Apr 18;390(15):1432-1433. doi: 10.1056/NEJMe2402364.

DOI:10.1056/NEJMe2402364

PMID:38631007

Abstract

摘要

相似文献

Adjuvant Immunotherapy for Kidney Cancer - A New Strategy with New Challenges.

N Engl J Med. 2024 Apr 18;390(15):1432-1433. doi: 10.1056/NEJMe2402364.

Adjuvant therapy in renal cell carcinoma: is resection still solely enough?

Future Oncol. 2021 Feb;17(6):633-636. doi: 10.2217/fon-2020-0982. Epub 2020 Dec 11.

Adjuvant pembrolizumab prolongs overall survival in renal cell carcinoma at high-risk of recurrence after nephrectomy. Can we do better than this?

Minerva Urol Nephrol. 2024 Oct;76(5):540-544. doi: 10.23736/S2724-6051.24.06114-7.

Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma.

N Engl J Med. 2024 Apr 18;390(15):1359-1371. doi: 10.1056/NEJMoa2312695.

Targeted therapy for metastatic renal cell carcinoma.

Cochrane Database Syst Rev. 2020 Oct 14;10(10):CD012796. doi: 10.1002/14651858.CD012796.pub2.

Pembrolizumab: first adjuvant immunotherapy in renal cell carcinoma?

Future Oncol. 2022 Feb;18(5):519-522. doi: 10.2217/fon-2021-1309. Epub 2022 Jan 24.

Adjuvant therapy after nephrectomy for renal cell carcinoma.

Asia Pac J Clin Oncol. 2018 Nov;14 Suppl 5:33-36. doi: 10.1111/ajco.13056.

Adjuvant immunotherapy in patients with renal cell carcinoma and urothelial carcinoma: A systematic review and network meta-analysis.

Int J Urol. 2024 Jan;31(1):25-31. doi: 10.1111/iju.15319. Epub 2023 Oct 15.

The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer.

Eur Urol. 2011 Sep;60(3):448-54. doi: 10.1016/j.eururo.2011.05.028. Epub 2011 May 17.

Pembrolizumab outperforms tyrosine kinase inhibitors as adjuvant treatment in patients with high-risk renal cell carcinoma after nephrectomy.

Eur Urol Oncol. 2022 Feb;5(1):120-124. doi: 10.1016/j.euo.2021.12.007. Epub 2022 Jan 3.

引用本文的文献

Immunological role and prognostic value of ITGA3 and ITGA5 in oral squamous cell carcinoma.

Sci Rep. 2025 Aug 17;15(1):30046. doi: 10.1038/s41598-025-16026-0.

Multi-omics analysis of bidirectional liquid-liquid phase separation signatures reveals immunotherapy response and prognosis in renal cell carcinoma.

BMC Cancer. 2025 Aug 13;25(1):1314. doi: 10.1186/s12885-025-14749-x.

Global, regional, and national burden of genitourinary cancers in 204 countries and territories, 1990-2021: a systematic analysis for the global burden of disease study 2021.

J Natl Cancer Cent. 2025 May 3;5(3):330-345. doi: 10.1016/j.jncc.2025.03.001. eCollection 2025 Jun.

Efficacy and safety of combining tislelizumab with capecitabine compared to capecitabine alone in the adjuvant treatment of biliary tract cancers: rationale and protocol design for a randomized clinical trial.

BMC Cancer. 2025 May 25;25(1):938. doi: 10.1186/s12885-025-14367-7.

Role of fructose in renal cell carcinoma progression.

Discov Oncol. 2025 May 23;16(1):897. doi: 10.1007/s12672-025-02688-9.

Do patients with intermediate-risk renal carcinoma who receive adjuvant pembrolizumab really benefit in recurrence-free survival? Analysis of a cohort of nephrectomies over 10 years.

World J Urol. 2025 May 16;43(1):307. doi: 10.1007/s00345-025-05599-0.

Turning the tide: pembrolizumab's triumph in adjuvant RCC therapy.

Med Oncol. 2024 Sep 5;41(10):242. doi: 10.1007/s12032-024-02486-3.

Clinical Importance of Focal Adhesion Kinase (FAK)-Src and Paxillin Expression in Renal Cell Carcinoma.

Cureus. 2024 Jun 19;16(6):e62706. doi: 10.7759/cureus.62706. eCollection 2024 Jun.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Suppr超能文献

Adjuvant Immunotherapy for Kidney Cancer - A New Strategy with New Challenges.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译